Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125370701 | 12537070 | 1 | I | 20160628 | 20160707 | 20160707 | EXP | US-SA-2016SA120895 | AVENTIS | 35.00 | YR | A | M | Y | 0.00000 | 20160707 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125370701 | 12537070 | 1 | PS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | U | UNK | 20839 | 75 | MG | TABLET | QD | |||||
| 125370701 | 12537070 | 2 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | U | UNK | 20839 | 75 | MG | TABLET | QD | |||||
| 125370701 | 12537070 | 3 | SS | ASPIRIN. | ASPIRIN | 1 | Unknown | UNK | 0 | ||||||||||
| 125370701 | 12537070 | 4 | C | CYTARABINE. | CYTARABINE | 1 | 0 | ||||||||||||
| 125370701 | 12537070 | 5 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | 0 | ||||||||||||
| 125370701 | 12537070 | 6 | C | ETOPOSIDE. | ETOPOSIDE | 1 | 0 | ||||||||||||
| 125370701 | 12537070 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 0 | 500 | MG | BID | |||||||||
| 125370701 | 12537070 | 8 | C | LANTUS | INSULIN GLARGINE | 1 | DOSE:26 UNIT(S) | 0 | QD | ||||||||||
| 125370701 | 12537070 | 9 | C | MOMETASONE FUROATE/FORMOTEROL FUMARATE | 2 | 0 | BID | ||||||||||||
| 125370701 | 12537070 | 10 | C | ALBUTEROL. | ALBUTEROL | 1 | 0 | QID | |||||||||||
| 125370701 | 12537070 | 11 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | 10 | MG | QD | |||||||||
| 125370701 | 12537070 | 12 | C | CARVEDILOL. | CARVEDILOL | 1 | 0 | 37.5 | MG | BID | |||||||||
| 125370701 | 12537070 | 13 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 125370701 | 12537070 | 14 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | 0 | 35 | MG | QD | |||||||||
| 125370701 | 12537070 | 15 | C | HYDRALAZINE | HYDRALAZINE HYDROCHLORIDE | 1 | 0 | 5 | MG | ||||||||||
| 125370701 | 12537070 | 16 | C | LEVETIRACETAM. | LEVETIRACETAM | 1 | 0 | 500 | MG | BID | |||||||||
| 125370701 | 12537070 | 17 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 100 | MG | CAPSULE | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125370701 | 12537070 | 7 | Type 2 diabetes mellitus |
| 125370701 | 12537070 | 9 | Asthma |
| 125370701 | 12537070 | 10 | Asthma |
| 125370701 | 12537070 | 11 | Hypertension |
| 125370701 | 12537070 | 12 | Hypertension |
| 125370701 | 12537070 | 13 | Hypertension |
| 125370701 | 12537070 | 14 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125370701 | 12537070 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125370701 | 12537070 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |